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Methodological recommendations for the diagnostics of EGFR 
gene mutations and ALK gene rearrangement in the selection 
of non-small-cell lung cancer patients to molecularly targeted 
therapies
Recommendations published in parallel „Onkologia w Praktyce Klinicznej” and „NOWOTWORY Journal of Oncology”
Abstract
Testing for EGFR gene mutations and ALK gene rearrangement is routinely used in advanced non-small-cell lung cancer for adequ-
ate patient selection to molecularly targeted therapies. We present Polish methodological recommendations for molecular analysis 
of EGFR and ALK genetic abnormalities. Recommendations specify clinical indications for testing, sample types and handling, as 
well as requirements for laboratories performing molecular diagnostics.
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Streszczenie
Badania molekularne mające na celu wykrycie mutacji genu EGFR i rearanżacji genu ALK wykonuje się rutynowo w zaawansowa-
nym niedrobnokomórkowym raku płuca (NDRP) w celu właściwej kwalifikacji chorych do terapii ukierunkowanych molekularnie. 
Przedstawiamy polskie zalecenia metodyczne prowadzenia diagnostyki molekularnej nieprawidłowości w genach EGFR i ALK. 
Zalecenia te opisują szczegółowo wskazania kliniczne do wykonania testów, rodzaj materiału oraz sposób postępowania z nim, 
a także wymagania stawiane laboratoriom wykonującym diagnostykę molekularną.
Słowa kluczowe: niedrobnokomórkowy rak płuca, mutacje genu EGFR, rearanżacja genu ALK, genetyczne testy diagnostyczne
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Introduction
The following guidelines represent the con-
sensus opinion of Polish experts in the field of 
pathomorphological and molecular diagnostics 
of non-small cell lung cancer (NSCLC). Along ra-
pid development of molecularly targeted NSCLC 
patients pharmacotherapy, there is a high rise in 
the number of diagnostic genetic testing allowing 
proper qualification for treatment. The guidelines 
are to provide methodological insight into all sta-
ges of adequately conducted diagnostics. By prin-
ciple, they will be the means of eliminating bad 
laboratory practices leading to faulty results of 
genetic testing or delay in the diagnostic process.
Pursuant to the official announcement of 
the Minister of Health regarding the list of reim-
bursed medicines, foodstuffs for special medical 
purposes and medical devices (1 March 2014), the 
molecularly targeted NSCLC patients treatment 
conducted as part of the drug scheme includes 
the administration of two epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors (TKI), 
erlotinib and gefitinib [1]. Both medicines are to 
be used in the first- and second-line treatment in 
patients with specific morphological subtypes of 
NSCLC, either locally advanced (unresectable) or 
metastatic, and the presence of activating muta-
tions of the EGFR gene [2]. Medicines authorised 
for marketing in the European Union, not covered 
with the reimbursement system in Poland yet, are 
expected to be introduced into the range of mole-
cularly targeted therapies of locally advanced and 
metastatic NSCLC patients in the nearest future. 
These comprise: irreversible EGFR HER2 and HER 
4 TKI - afatinib and ALK (anaplastic lymphoma 
kinase) TKI - crizotinib.
1. Clinical recommendations for the diagnostics of 
EGFR gene and ALK gene rearrangement in NSCLC 
patients
A. Recommendation: Confirmed presence of EGFR 
gene mutations or ALK gene rearrangement in 
cancer cells is the key criteria for NSCLC patient 
qualification for molecularly targeted therapies 
using EGFR TKI or ALK TKI [2].
B. Recommendation: The decision to run ge-
netic testing in an NSCLC patient should 
be taken by an oncologist or pulmonologist 
subject to individual assessment of patient 
condition and clinical indications for mo-
lecularly targeted treatment. EGFR gene 
mutations testing ought to be performed in 
patients diagnosed with NSCLC other than 
squamous cell carcinoma; whereas ALK gene 
rearrangement testing - in patients diagnosed 
with adenocarcinoma or including an ade-
nocarcinoma component. Differentiation or 
histologic grade has no impact on indications 
for molecular diagnostics [3-8]. 
 Genetic testing is not recommended if hi-
stopathological analysis of cancer specimen 
reveal pure squamous-cell lung cancer or 
small-cell lung cancer or carcinoid. In the 
event the standard hematoxylin and eosin 
(H+E) staining does not allow for NSCLC sub-
type determination, histochemical (to identify 
mucilage in cancer cells) and/or immuno-
chemical staining (IHC) is obligatory. It is 
recommended that expression of a minimum 
two markers be determined: TTF-1, which 
helps differentiate adenocarcinoma and p63 
or p40, which expression favours squamous 
cell carcinoma. In the case of cytological 
material, every IHC should be preceded by 
qualification for genetic diagnostics [3−8].
 Molecular testing for EGFR gene mutations 
is acceptable provided that it is impossible 
to determine the morphological subtype of 
NSCLC (not otherwise specified, NOS) [5-8].
C. Recommendation: Demographic criteria, 
such as sex, race or history of smoking do 
not affect the indications for EGFR gene mu-
tations or ALK gene rearrangement testing in 
NSCLC patients. Considering the smoking/
lack of smoking history is acceptable provi-
ded that testing is conducted on the basis of 
hypocellular sample or cytological material 
in which the presence of adenocarcinoma 
component was not completely excluded 
(NSCLC NOS) [6−8].
D. Recommendation: Specimen originating from 
primary NSCLC and from metastases should 
be treated as equally suitable for determining 
the presence of EGFR gene mutations and ALK 
gene rearrangement. There is no justification 
for simultaneous testing of several tissue 
samples of the same tumour [6−8].
2. Principles of molecular testing for EGFR gene 
mutations and ALK gene rearrangement
A. Recommendation: It is recommended that 
the oncologist or pulmonologist ordering 
pathomorphological testing of specimen of 
a patient suspected of locally advanced or 
metastatic NSCLC (stage IIIB or IV according 
to the seventh edition of TNM classification 
[9-10]) also instruct in writing that genetic 
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testing be performed, if justified by morpho-
logical diagnosis, volume, and quality of 
available sample. In that case, it is advised 
that a pathologist take decision regarding 
possible genetic testing for EGFR gene mu-
tations and ALK gene rearrangement at the 
time of microscopic diagnosis. In default 
of relevant instructions, secured material 
should be transferred for genetic testing im-
mediately after reception of a written order 
of the attending physician [6−8].
 It is requisite that genetic testing be perfor-
med in lower-stage non-small cell lung can-
cer at disease recurrence or if unresectable, 
provided that qualification for molecularly 
targeted treatment is considered. 
B. Recommendation: It is recommended that 
EGFR gene mutations testing be conducted 
first. ALK gene rearrangement determination 
in adenocarcinoma patients should be perfor-
med upon previous exclusion of the presence 
of somatic mutations in EGFR gene. Nowa-
days, there is insufficient clinical evidence 
to justify the analysis of other molecular 
markers in NSCLC patients [6−8].
C. Recommendation: The turnaround for EGFR 
gene mutations and/or ALK gene rearrangement 
tests should not exceed 10 working days from 
the time tissue samples are delivered to the 
genetic laboratory. Nevertheless, it is recom-
mended that the turnaround time for genetic 
testing be a maximum of 5 working days [6−8].
D. Recommendation: It is recommended that 
laboratories where the turnaround time for 
EGFR gene mutations and ALK gene rearran-
gement tests exceeds 10 working days adjust 
their procedures and methods of analyses 
accordingly [6−8].
E. Recommendation: The time of preparing archi-
ve materials by a pathomorphological laborato-
ry and delivering them to a genetic laboratory 
should not exceed 3 days from the order date. 
The above period may be extended if morpho-
logical reassessment is required [6-8].
3. Requirements to be met by genetic laboratories 
regarding EGFR gene mutations and ALK gene 
rearrangement testing
A. Recommendation: Operational rules regar-
ding laboratories performing genetic testing 
of predictive factors for molecularly targeted 
therapies in neoplastic diseases shall follow 
the regulations set forth in the Laboratory 
Diagnostics Act of 27 July 2001 (as amended) 
and the Ministry of Health Regulation of 21 
January 2009 amending the regulation on 
the quality standards for medical diagnostic 
and microbiological laboratories (Appendix 
3) [11, 12]. Recommendations B to D specify 
laboratory operational rules included in Ap-
pendix 3 to the MH Regulation.
B. Recommendation: Genetic testing may be 
performed solely under the supervision of the 
laboratory diagnostician or a physician who 
is a staff member of the laboratory performing 
genetic testing and: 1) is a specialist in me-
dical laboratory genetics and is permanently 
employed by the laboratory performing ge-
netic testing or 2) has a minimum of two-year 
genetic laboratory work experience or 3) has 
been employed for a continuous period of 
five years by a genetic laboratory performing 
EGFR gene mutations and ALK gene rearran-
gement testing. 
C. Recommendation: EGFR gene mutations 
and ALK gene rearrangement is a standard 
procedure to evaluate non-heritable genetic 
disorders in cancer cells. Thus, obtaining a 
separate patient consent form to perform ge-
netic testing is unnecessary. General consent 
to perform diagnostic testing, including but 
not limited EGFR gene mutations and ALK 
gene rearrangement, should be obtained at 
admission to hospital and stored with other 
medical records of the patient.
D. Recommendation: It is recommended that ge-
netic laboratories performing EGFR gene mu-
tations and ALK gene rearrangement testing 
carry out period internal quality assessment 
and participated in external quality assess-
ment (EQA) programmes [12]. Polish genetic 
laboratories have access to EQA programmes 
conducted by renown genetic diagnostics 
quality control centers (such as European 
Molecular Quality Network, European So-
ciety of Pathology) and should have quality 
certificates issued by at least one of them. 
E. Recommendation: It is recommended that 
a Polish external quality assessment pro-
gramme involving EGFR gene mutations and 
ALK gene rearrangement testing in NSCLC 
patients specimen be developed.
Requirements regarding the methods and range  
of EGFR gene mutations
A. Recommendation: Genetic testing for EGFR 
gene mutations ought to be performed only 
on properly secured material: 1) formali-
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ne-fixed and paraffin-embedded samples 
(preferred material due to high stability and 
suitability for genetic testing even after seve-
ral days from collection); 2) freshly collected 
tissues; 3) frozen tissues; 4) alcohol-fixed 
tissues. Specimen prepared with the use of 
other fixatives, especially ones with heavy 
metals content or decalcifying solutions and 
of acidic environment, should not be used 
for EGFR gene mutations assessment. It is 
recommended that the times of tissue fixation 
in a 10% buffered formalin, i.e. 6-48 hours, be 
strictly followed. Every case of noncomplian-
ce with routine laboratory procedures, in 
particular with recommended fixation times 
and methods of paraffin embedding should 
be recorded in the pathomorphological report 
due to their potential effect on tumour tissue 
DNA integrity [5−8].
B. Recommendation: Cytology specimen, in par-
ticular cytoblocks or smears on glass slides, 
are suitable for EGFR gene mutations analysis. 
Cell suspensions used for cytoblock prepara-
tion should be fixed in 10% buffered formalin 
or 70% ethanol solution for 6−48 hours. It is 
advised that each laboratory runs a complete 
cytology specimen development validation 
procedure, including fixation and genetic 
analysis for EGFR gene mutations [5−8, 13, 14]. 
C. Recommendation: It is recommended that 
the choice of representative material for de-
termining EGFR gene mutations be made by 
a pathologist. Cancer cells and necrotic foci 
rate assessment, and in the case of cytology 
specimen — also cancer cell count — are 
obligatory. It is recommended that paraffin 
tissue blocks or cytoblocks be mass-produ-
ced according to the following scheme: 1. 3 
µm-thick sections intended for cancer cell 
content analysis (hematoxylin and eosin 
staining, H+E); 2. 8−10 µm-thick sections 
intended for DNA isolation (in the case of 
hypercellular material several specimen 
8-10 µm-thick are allowed); 3. and 4. 3−5 
µm-thick sections are intended for ALK gene 
rearrangement testing (FISH and IHC me-
thods, if a given laboratory uses said method 
for initial ALK gene rearrangement diagno-
stics); 5. 3 µm-thick sections are intended for 
reassessment of cancer cells content [6−8]. 
D. Recommendation: Diagnostic specimen-iso-
lated DNA quantity and quality assessment 
is obligatory [6-8].
E. Recommendation: Genetic analysis of cytolo-
gy specimen fixed on a glass slide should be 
performed in smears stained with hematoxy-
lin and eosin (H+E). The use of immunohi-
stochemical stain slides is not recommended 
[6−8, 13, 14].
 It is recommended that cancer cells iden-
tification and location in the specimen be 
performed by a pathologist. Genetic labo-
ratory procedure should involve specimen 
incubation in xylene solution for a minimum 
of 4-6 hours, optimally 12 hours, cover glass 
removal and DNA isolation from cells me-
chanically removed from the slide from the 
spots previously indicated by the pathologist 
[6−8, 13, 14]. 
F. Recommendation: Genetic laboratory is obli-
ged to establish the minimum rate of cancer 
cells content needed for reliable assessment 
of EGFR gene mutations during internal qu-
ality control [6−8, 12]. 
 Microdissection of cancer cells from a given 
specimen to increase the cancer cell rate is 
allowed [6−8]. 
G. Recommendation: DNA isolation requires 
the use of reagent sets intended for in vitro 
diagnostics (CE-IVD symbol) [6−8, 12]. 
H. Recommendation: Genetic laboratory may 
avail of various EGFR gene mutations deter-
mination methods provided that they have 
been validated and specified in accordance 
with binding Polish regulations (Act of 18 
March 2011 — establishing the Office for Re-
gistration of Medicinal Products, Medical De-
vices and Biocides). DNA isolation requires 
the use of reagent sets intended for in vitro 
diagnostics (CE-IVD symbol) [6−8, 12]. 
 The use of polymerase chain reaction (PCR)
-based methods, including above all real-time 
PCR, is recommended. The sensitivity of the 
EGFR gene mutations analysis method must 
constitute a reliable analysis of specimen 
containing at least 50% of cancer cells. Sanger 
sequencing genetic analysis may be applied to 
such specimen. However, it is recommended 
that more sensitive molecular testing methods 
allowing EGFR gene mutations identification 
in specimen with at least 10% cancer cell 
content be applied [6−8, 15, 16].
 It is recommended that every laboratory with 
no technological means to perform genetic te-
sting of low cancer cell specimen transfer the 
sample to other laboratory without delay and 
inform the ordering party accordingly [6−8].
I. Recommendation: It is required that every labo-
ratory have at its disposal methodology allowing 
identification of all EGFR gene mutations of at 
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least 1% incidence rate (amongst the known 
EGFR gene mutations) [6−8, 16] (Table 1).
J. Recommendation: It is recommended that 
specimen testing for T790M mutation of the 
EGFR gene (related to EGFR TKI resistance) be 
performed with the use of high sensitivity me-
thods allowing reliable analysis of specimen 
with at least 5% cancer cells content [6−8].
K. Recommendation: It is not recommended 
that IHC reactions be used for determining 
EGFR protein expression and EGFR gene copy 
number analysis by fluorescent or chromoge-
nic in situ hybridization — for qualification 
for EGFR tyrosine kinase inhibitor therapy. 
Furthermore, KRAS gene mutations testing 
for qualification for EGFR TKI therapy is not 
recommended, wither [2, 6−8].
Requirements regarding the methods and range of 
ALK gene rearrangement
A. Recommendation: The presence of ALK gene 
rearrangement in the analysed specimen must 
be confirmed by fluorescent in situ hybridiza-
tion (FISH) using dual-labelled break-apart 
probes. Immunohistochemical reaction may 
be used as a screening tool for qualification 
of specimen for ALK rearrangement testing 
with FISH provided that previous validation 
is conducted. It is recommended that sets 
certified for in vitro application (CE-IVD 
symbol) be used [6, 15−19].
B. Recommendation: RT-PCR is not recommen-
ded as an alternative to FISH for ALK gene 
rearrangement testing [6, 18−19]. 
C. Recommendation: It is recommended that 
the choice of representative material for de-
termining ALK gene rearrangement be made 
by a pathologist in accordance with instruc-
tions set forth in Recommendation C Point 
4. Furthermore, it is required that cancer 
cells architecture or cancer cells location be 
established in the cytology specimen and that 
its quality be determined.
 Specimen for ALK gene rearrangement te-
sting should be stored in paraffin blocks 
(histological material or cytoblocks). Reliable 
determination of ALK gene rearrangement 
in H+E- or immunohistochemical-stained 
cytology is not possible [6, 18, 19].
D. Recommendation: It is recommended that 
ALK gene rearrangement testing be performed 
by a laboratory diagnostician or a pathologist. 
Simultaneous application of the positive and 
negative control is a prerequisite. 
 It is recommended that visual assessment 
of specimen be always performed by two 
independent observers experienced in in-
terpretation and analysis of FISH and IHC 
findings [6, 18, 19]. 
E. It is recommended that a pathologist expe-
rienced in interpretation and analysis of 
FISH staining results participate in specimen 
assessment. 
F. Recommendation: Diagnostic testing for ALK 
gene mutation related to acquired resistan-
ce to ALK tyrosine kinase inhibitors is not 
required [6, 19].
Reporting EGFR gene mutations and ALK gene 
rearrangement genetic testing
A. Recommendation: The EGFR gene muta-
tions and ALK gene rearrangement report is 
required to include test findings presented 
according to the Human Genome Variation 
Society (HGVS) terminology [20] and its cle-
arly-worded interpretation comprehensible 
for an oncologist or a pulmonologist and a 
pathologist.
B. Recommendation: It is recommended that 
the EGFR gene mutations testing report inc-
lude, in particular: 1) data allowing definite 
patient identification; 2) identification data 
of the centre ordering genetic testing and 
the surname of the ordering oncologist or 
pulmonologist; 3) identification data of the 
pathomorphological laboratory where the 
pathomorphological analysis was performed 
and the surname of the pathologist conduc-
ting the analysis; 4) the reference no. of speci-
men referred for genetic testing accompanied 
by detailed pathomorphological diagnosis 
and specimen cancer cells content, and im-
munohistochemical findings, if any; 5) de-
scription and sensitivity of the method used 
for EGFR gene mutations assessment; 6) list 
of mutations tested; 7) descriptive evaluation 
of the quality of isolated DNA; 8) results of 
genetic testing along clinical interpretation; 
9) specimen reception date and specimen 
analysis date; 10) signature of the laboratory 
diagnostician performing the assay and the 
person authorising the results: a laboratory 
diagnostician specialising in medical labora-
tory genetics, a pathologist or clinical genetics 
specialist. It is not recommended that genetic 
testing report contain detailed suggestions re-
garding the selection of a specific molecularly 
targeted medicine [6−8, 12].
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Table 1.  Known mutations in the EGFR gene (NM_005228.3) with at least 1% incidence amongst all EGFR gene mutations [16]
EGFR 
gene 
exon
EGFR  
gene codon
Mutation  Nucleotide substitution Estimated incidence amongst 
all EGFR mutations (%)
18. E709 p.E709K c.2125G>A 1
p.E709A c.2126A>C
p.E709G c.2126A>G
p.E709V c.2126A>T
p.E709D c.2127A>C,
c.2127A>T
p.E709Q c.2125G>C
G719 p.G719S c.2155G>A 2–5
p.G719A c.2156G>C
p.G719C c.2155G>T
p.G719D c.2156G>A
19. K739 Insertions
18-pz
1
I740
P741
V742
A743
I744
E746 Deletions (bp)
9
12
15
18
24
45
L747
R748
E749
A750
T751
S752
P753
20. S768 Insertions (bp)
3
9
4–10
V769
D770
N771
P772
H773
V774
S768 p.S768I c.2303G>T 1–2
T790 p.T790M c.2369C>T 2
21. L858 p.L858R c.2573T>G 40
p.L858M c.2572C>A
L861 p.L861Q c.2582T>A 2–5
p.L861R c.2582T>G
bp — base pair
Paweł Krawczyket al., Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement
443www.pneumonologia.viamedica.pl
C. Recommendation: ALK gene rearrangement 
genetic testing report should include data 
stipulated in Points 1−4 and 6−7 of Recom-
mendations B Point 6, and, obligatorily, a 
description of the method used for ALK gene 
rearrangement testing, information regarding 
the number of cell nuclei assessed (FISH) and 
the level of EML4-ALK protein expression 
(IHC) [6−8].
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